Form 8-K - Current report:
SEC Accession No. 0001193125-26-237207
Filing Date
2026-05-22
Accepted
2026-05-22 17:28:16
Documents
12
Period of Report
2026-05-19
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K d131489d8k.htm   iXBRL 8-K 35497
  Complete submission text file 0001193125-26-237207.txt   188539

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA tpst-20260519.xsd EX-101.SCH 4210
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE tpst-20260519_def.xml EX-101.DEF 13696
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE tpst-20260519_lab.xml EX-101.LAB 22680
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tpst-20260519_pre.xml EX-101.PRE 14664
16 EXTRACTED XBRL INSTANCE DOCUMENT d131489d8k_htm.xml XML 5510
Mailing Address 2000 SIERRA POINT PARKWAY SUITE 400 BRISBANE CA 94005
Business Address 2000 SIERRA POINT PARKWAY SUITE 400 BRISBANE CA 94005 415-798-8589
Tempest Therapeutics, Inc. (Filer) CIK: 0001544227 (see all company filings)

EIN.: 451472564 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35890 | Film No.: 261015152
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)